Law firms that want a piece of the burgeoning stem cell research industry — which could be flush with California’s potential $3 billion investment over the next decade — will have to rethink their approach to the fledgling industry.
Optimistically, there may be two to five years before significant research moves from the laboratory to commercial development, but “lawyers who hope to get in on this will have to do what we do, educate themselves not only about legal issues but the science,” said Michael Shuster, intellectual property attorney with Fenwick & West of Mountain View, Calif.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
